Skip to main content
. 2023 Jan 23;12(3):e027540. doi: 10.1161/JAHA.122.027540

Figure 3. Free serum sLOX‐1 levels in patients with T2DM receiving single (A) or multiple (B) doses of MEDI6570 or placebo.

Figure 3

Dashed gray line indicates lower limit of quantification. In a categorical analysis, sLOX‐1 suppression of 90% relative to baseline or to below LLOQ was achieved in 66.7% (P=0.003), 83.3% (P=0.001), and 90.0% (P<0.001) of participants at day 70, respectively, following 3 doses of 90, 150, and 250 mg of MEDI6570. LLOQ indicates lower limit of quantification; sLOX‐1, soluble lectin‐like oxidized low‐density lipoprotein receptor 1; and T2DM, type 2 diabetes.